Moderna Share Price Forecast February 2022 – Time to Buy MRNA?
Please note that we are not authorised to provide any investment advice. The content on this page is for information purposes only.
Shares of vaccine manufacturer Moderna (NASDAQ: MRNA) are in the green today after closing at $151.81 as of February 16th (19:59 EST). Moderna shares have fallen significantly from the high days of 2021. In 2022, the once flying shares decreased by 33% in January and are now down more than 40% year to date.
Moderna – Technical Analysis
Moderna’s financial statement indicated a market cap of $61.551 billion with total assets worth $20.923 billion. Revenue for 2020 was at $803.39 million with a profit margin of -92.99% compared to $60.21 million in 2019. Moderna’s full-year 2021 vaccine revenue is expected to be total $17.5 billion. It also expects 2022 revenue to be $18.5 billion which could get higher company signs more advance purchase agreements.
Oscillators such as Relative Strength Index (14)(36.99), Stochastic %K (14, 3, 3)(26.19), Commodity Channel Index (20)(−80.14), Average Directional Index (14)(30.77) and Awesome Oscillator(−30.74) are neutral. Moving averages such as Exponential Moving Average (10)(156.66), Simple Moving Average (10)(157.17), Exponential Moving Average (20)(166.84), Simple Moving Average (20)(159.19) and Exponential Moving Average (30)(179.41) are indicating a sell action.
67% of all retail investor accounts lose money when trading CFDs with this provider
Recent Developments
Moderna shares looked like a sure shot winner back in 2020 when the pandemic surfaced. At one point, its market cap approached $200 billion. Covid-19 is expected to drive much of the company’s revenue in the immediate future. Its expected revenue is at least $18.5 billion in 2021 from its vaccine based on advanced purchase agreements that have already been signed. The total is expected to cross $20 billion. Moderna has set clear goals for developing a combination vaccine for COVID-19, flu, respiratory syncytial virus (RSV), and the OC43 human coronavirus.
Moderna has also been working on cytomegalovirus (CMV) vaccine candidate which is in late-stage testing. The company expects the vaccine to generate peak sales of between $2 billion and $5 billion if approved. The company’s messenger RNA (mRNA) technology could be used in vaccines and therapies targeting a wide range of diseases. It also has almost a dozen clinical programs outside of CMV and COVID-19.
Should You Buy MRNA Shares?
Moderna was founded in 2010 and had ever launched a product on the market before the pandemic. But the coronavirus vaccine allowed it to end the third quarter with $15.3 billion in cash and equivalents. It’s main target is o develop a raft of viruses with its mRNA-based approach to vaccination. This would give the company an edge over its competitors as the vaccine yields potential cost savings.
Moderna’s lower price might be a buying opportunity for investors, based on the company’s market cap of less than $60 billion and its growth prospects. The shares now offer the company’s market cap of less than $60 billion and its growth prospects. But there is uncertainty regarding how much recurring revenue Moderna will be able to count on from its COVID-19 vaccine after 2022.
The company’s growth prospects make the shares attractive again. However, this is only applicable to investors who are in it for the long term. Moderna’s shares could be highly volatile and could decrease even more. It faces risks related to pipelines and uncertainties due to the pandemic. But long term investors should not worry about its temporary fluctuations and headwinds. There are high chances that Moderna could deliver market-beating returns over the next decade and beyond if it can deliver on the promise of its mRNA platform.
Buy MRNA Stock at eToro from just $50 Now!
